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Methaemoglobinaemia is a potentially life-threatening complication of problem drug use. This is a case report of a 29-year-old
man who presented himself cyanosed after a cocaine binge. It highlights the diagnosis and management of this condition from an
acute medical perspective.
1. Case Presentation
A 29-year-old man presented himself to the emergency
department after noticing that his lips and ﬁngers had
turned blue. He had been on a cocaine binge preceding his
admission. He estimated that he had been taking at least
14 grams over a period of ﬁve days. He felt short of breath
on moderate exertion but denied chest pain or any other
systemic symptoms. He had been using cocaine regularly
for at least ten years, always via the nasal passageways,
never injected, and denied taking any other recreational
drugs. He was not on any prescription or over-the-counter
medications. His only past medical history was of alcohol
dependence, though he had not drunk in excess for at least
ten months. There was no signiﬁcant family history.
He was alert and coherent, but slightly anxious. He was
apyrexial, his noninvasive blood pressure was 135/96mmHg,
andhisheartratewas85beats/min.Hewastachypnoeicwith
a respiratory rate of 18/min. There was marked cyanosis of
his ﬁngers and lips, and he was, immediately upon arrival
in the emergency department, commenced on high ﬂow
oxygen. His saturation measured by pulse oximetry (SO2)
was 86% on 15 L of oxygen given via a nonrebreathing mask.
Arterial blood gasses showed H+ 50.9nmol/L, pCO2 5.8kPa,
pO2 72.3kPa, lactate 0.7mmol/L, bicarbonate 26.0mmol/L,
CO Hb 0.0%. His oxygen saturation on the blood gas (O2
Hb) was 66.6% and his methaemoglobin (Met Hb) level
32.9%. Chest X-Ray, ECG, full blood count, and routine
biochemistry were unremarkable.
A diagnosis of methaemoglobinaemia was made, and he
received one dose of methylene blue (1mg/kg) intravenously
overﬁveminutes.Hewastransferredtothehighdependency
unit where he continued to receive high ﬂow oxygen and was
closely monitored.
His methaemoglobin levels, as well as his saturation,
improved steadily over the next hours (Table 1). He made
a full recovery and was discharged home the same evening





to adulterants, cheaper substances that are being mixed
with the pure cocaine base to increase the proﬁts from
selling the drug. Local anaesthetics are being used as they
will produce a similar sensation when applied to mucosal
surfaces as unadulterated cocaine [1]. Benzocaine is often
implied in acquired methaemoglobinaemia, though its use
as adulterant does vary between countries. Benzocaine is the
most frequently found cutting agent in the UK [2] while a
recent French study failed to show its signiﬁcant use there
[3].
Methaemoglobinaemia is caused by oxidation of the
iron molecule in the heme group to the ferric state (Fe
3+). This renders it unable to carry oxygen and causes a
functionalanaemia.Bloodnormallycancontainabout1%of
methaemoglobin. Substances that put high oxidative stresses
ontohaemoglobinwillincreasethelevelabovenormal.Well-
recognized causes for this are local anaesthetics (especially2 Case Reports in Medicine
Table 1
Time 23:16
(admission) 00:29 02:23 15:35
Met Hb in % 32.9 16.9 1.9 0.2
O2 Hb in % 66.6 82.4 93.1 98
SO2 i n % 8 6 8 99 19 7
prilocaine, benzocaine), antibiotics (dapsone, trimethoprim,
sulfonamides), aniline dyes, and metoclopramide, as well
as nitrates. Blood that contains signiﬁcant amounts of
methaemoglobin has a characteristic dark reddish-brown
colour. Above concentrations of 1.5g/dL (Met Hb 10–15%),
this will cause cyanosis even in the absence of elevated
deoxyhaemoglobin levels. At relatively low levels this will
lead to a cyanotic but asymptomatic patient. Typically,
the cyanosis will not improve after increasing the oxygen
supply. Symptoms in otherwise healthy individuals will start
at methaemoglobin levels of 30% or more. These will be
related to oxygen deﬁciency in organs with high demands,
that is, the cardiovascular and central nervous system.
Patients will experience headaches, lightheadedness, anxiety,
dyspnoea, palpitations, and somnolence. Signiﬁcant toxicity
will occur at methaemoglobin levels of 50% and over. This
will include cardiac arrhythmias, delirium, seizures, coma
as well as a profound metabolic acidosis. Death will occur
at concentrations above 60% [4], though in patients with
comorbidities this can occur at much lower levels.
Methaemoglobin interferes with traditional (not multi-
wavelength) pulse oximetry. In patients with relatively low
methaemoglobin levels this will give falsely low oxygen
saturations. Paradoxically, it will also lead to falsely elevated
oxygen saturations in the presence of signiﬁcant concen-
trations [5]. Arterial blood gasses will often show normal
PaO2 levels but falsely low O2 saturations. This diﬀerence
between the oxygen saturation from the blood gas analysis
and the saturation, as measured by the saturation probe, is
commonly referred to as the “saturation gap.” It suggests the
presence of a haemoglobin derivate that is not transporting
oxygen. In the presence of cyanosis, this is highly suggestive
of methaemoglobinaemia [6]. In severe cases there will be
a signiﬁcant acidosis. Lactate levels, urea, and electrolytes,
as well as a creatinine kinase and 12 lead ECG, can help
to assess the degree of tissue hypoperfusion and end-
organ damage. These investigations will also point towards
other cocaine-related toxicities. A pregnancy test should be
performed in women of childbearing age. A urine screen
for drug metabolites can help in unclear cases. Sometimes
a blood ﬁlm will show Heinz bodies in the erythrocytes,
inclusions of denatured haemoglobin [7]. Good history
taking is paramount to identify the possible oﬀending
agent and to distinguish primary from secondary causes
of methaemoglobinaemia. In case of internal concealment
of cocaine (“body packers”), oral purgation and sometimes
surgical removal may be necessary [8]. Cases with severe
toxicity, decreased level of consciousness, or multiple organ
failure should be treated after obtaining advice from the
National Poisons Information Service or similar and in a
high dependency or intensive care environment.
Healthy and asymptomatic patients with low levels of
methaemoglobin may only need administration of high ﬂow
oxygen and observation. As long as the oﬀending agent has
been removed, Met Hb levels will return to normal within
36 hours [9]. Methylene blue (methylthioninium chloride)
is the antidote of choice if methaemoglobin levels have
reached 30% or if there is symptomatic hypoxaemia or
ischaemia [10]. It leads to the reduction of methaemoglobin
both via the NADPH-methaemoglobin reductase as well as
through its own intermediary, leucomethylene blue [11].
The initial dose is 1mg/kg bodyweight given intravenously
over ﬁve minutes. Eﬀects will be measurable within 30
minutes to one hour. In severe toxicity, this may have
to be repeated. Failure to respond to methylene blue
suggests G6PD deﬁciency where it can also cause profound
haemolysis. Repeated or high doses can lead to a para-
doxical increase in methaemoglobin [12]. Its eﬀects during
pregnancy are unsure, and potential risks of teratoxicity
need to be considered [13]. It can cause blue discolouration
of the urine as well as of the sclera [14]. Other rare but
serious side eﬀects are related to its MAO-inhibitor action
[15], and it has been implied in the serotonin syndrome
[16]. The latter is a potentially life-threatening condition
caused by excessive serotonergic activity in the nervous
system. Features include mental status changes, autonomic
instability, and neuromuscular hyperactivity [17]. Patients
who have been on selective serotonin reuptake inhibitor
antidepressants (SSRIs) or clomipramine and are treated
with methylene blue should be observed for CNS eﬀects
for up to four hours after administration [18]. Alternative
treatments which have been successfully used in signiﬁcant
methaemoglobinaemia, or in patients that are unable to
take methylene blue, are hyperbaric oxygen and exchange
transfusions [19].
The prognosis of methaemoglobinaemia is determined
bythedegreeofend-organdamage.Mild-to-moderatesevere
cases will make a complete and swift recovery.
Recurrentpresentations,partialornonresponsetometh-
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